CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Intestinal stem cells identified as active defenders against Salmonella infection May 12, 2026 Research shows the positive impact of physical activity on young people’s well-being February 21, 2025 Study shows impact of primary health care in reducing child mortality in Latin America May 16, 2024
Research shows the positive impact of physical activity on young people’s well-being February 21, 2025